A PHASE I TRIAL OF RADIOIMMUNOTHERAPY (Y-90 CT8466), GEMCITABINE AND HEPATIC

放射免疫治疗 (Y-90 CT8466)、吉西他滨和肝脏的 I 期试验

• 批准号: 7982065
• 负责人: JEFFREY Y WONG
• 金额: $ 0.7万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7982065
• 关键词: 90Y; Ablation; Adjuvant Therapy; Biodistribution; Cancer Patient; Clinical Research; Colorectal Cancer; Computer Retrieval of Information on Scientific Projects Database; Dose; Excision; Feasibility Studies; Funding; Grant; Hepatic; Image; Indium-111; Infusion procedures; Institution; Intravenous; Maximum Tolerated Dose; Metabolism; Metastatic Neoplasm to the Liver; Nuclear; Operative Surgical Procedures; Organ; Phase I Clinical Trials; Proteomics; Radiation; Radioimmunotherapy; Research; Research Personnel; Resources; Source; Toxic effect; Tumor Debulking; United States National Institutes of Health; gemcitabine; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The objectives are to determine the maximum tolerated dose (MTD) and associated toxicities of concurrent hepatic arterial infusion (HAI) fluorodeoxypyrimide (FUdR) and intravenous gemcitabine combined with intravenous Yttrium-90 chimeric T84.66 in colorectal cancer patients after hepatic resection or maximum surgical debulking (to <3cm) of liver metastases; to study the feasibility and toxicities of such adjuvant therapy following resection and/or ablation of liver metastases; to evaluate the biodistribution, clearance and metabolism of Yttrium-90 and Indium-111 chimeric T84.66 administered intravenously; to estimate radiation doses to whole body, normal organs and tumor through serial nuclear imaging; to correlate proteomic profiles pre and post-therapy with toxicities and anti-tumor effects.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 目的是确定肝切除或最大手术后结直肠癌患者同时肝动脉输注（HAI）氟脱氧嘧啶（FUdR）和静脉注射吉西他滨联合静脉注射钇90嵌合T84.66的最大耐受剂量（MTD）和相关毒性肝转移瘤减瘤（至<3cm）；研究肝转移瘤切除和/或消融后此类辅助治疗的可行性和毒性；评估静脉注射钇90和铟111嵌合体T84.66的生物分布、清除和代谢；通过连续核成像估算全身、正常器官和肿瘤的辐射剂量；将治疗前和治疗后的蛋白质组学特征与毒性和抗肿瘤作用相关联。